Skip to main content
. 2022 Nov 6;31(6):e13747. doi: 10.1111/ecc.13747

TABLE 2.

Adverse events reported in >10% of patients (all grades; safety population; N = 76)

Adverse event, n (%) All grades Treatment related Grade 3/4
Fatigue 49 (64.5) 43 (56.6) 3 (3.9)
Alopecia 28 (36.8) 26 (34.2) 0
Nausea 27 (35.5) 24 (31.6) 2 (2.6)
Constipation 23 (30.3) 14 (18.4) 0
Peripheral neuropathy 21 (27.6) 16 (21.1) 1 (1.3)
Decreased appetite 17 (22.4) 13 (17.1) 1 (1.3)
Diarrhoea 16 (21.1) 8 (10.5) 1 (1.3)
Headache 15 (19.7) 5 (6.6) 0
Dyspnoea 15 (19.7) 7 (9.2) 4 (5.3)
Neutropenia 14 (18.4) 13 (17.1) 7 (9.2)
Vomiting 13 (17.1) 10 (13.2) 3 (3.9)
Pyrexia 10 (13.2) 7 (9.2) 0
Mucosal inflammation 10 (13.2) 8 (10.5) 1 (1.3)
Arthralgia 9 (11.8) 3 (3.9) 1 (1.3)
Cough 9 (11.8) 3 (3.9) 0
Stomatitis 9 (11.8) 8 (10.5) 0
Palmar‐plantar erythrodysaesthesia syndrome 8 (10.5) 7 (9.2) 1 (1.3)

Note: An adverse event with the same preferred term for the same patient was counted only once. If a patient had the same event more than once, the worst National Cancer Institute Common Terminology Criteria grade was selected within a same group of system/organ/class and preferred term per Medical Dictionary for Regulatory Activities version 17.0.